Compare PKE & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | OABI |
|---|---|---|
| Founded | 1954 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.4M | 696.4M |
| IPO Year | 1994 | 2021 |
| Metric | PKE | OABI |
|---|---|---|
| Price | $25.69 | $4.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $42.50 | $8.33 |
| AVG Volume (30 Days) | 262.1K | ★ 1.2M |
| Earning Date | 10-08-2026 | 10-30-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 93.10 | 6.56 |
| EPS | ★ 0.37 | N/A |
| Revenue | N/A | ★ $18,666,000.00 |
| Revenue This Year | $16.24 | $87.73 |
| Revenue Next Year | $17.78 | $25.31 |
| P/E Ratio | $69.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.25 | $1.32 |
| 52 Week High | $39.86 | $5.43 |
| Indicator | PKE | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 28.52 | 56.57 |
| Support Level | $25.70 | $1.93 |
| Resistance Level | $25.82 | $5.06 |
| Average True Range (ATR) | 1.19 | 0.34 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 8.81 | 69.23 |
Park Aerospace Corp is an aerospace company that develops and manufactures composite materials used to produce composite structures for the aerospace market. Its products include film adhesives, lightning strike protection materials, specialty ablative materials for rocket motors and nozzles, and materials for radome applications. The Company offers composite materials designed for hand lay-up and automated fiber placement (AFP) manufacturing applications, which are used in jet engines, large and regional transport aircraft, military aircraft, unmanned aerial vehicles (UAVs), business jets, general aviation aircraft, and rotary wing aircraft. It operates in North America, Asia, and Europe, with North America generating maximum revenue.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.